VRDN Stock — Viridian Therapeutics, Inc.

Viridian Therapeutics, Inc. (VRDN)

Updated October 16, 2026.

VRDN is a Stock. Total return is -99.1% over the past 12.3 years, 478.2 points behind SPY at 379.1%.

Viridian Therapeutics discovers, develops, and commercializes treatments for serious and rare diseases, with a focus on therapies targeting IGF-1R to treat thyroid eye disease and other conditions, along with a pipeline of engineered inhibitors designed to modulate immune responses. As a clinical-stage biopharmaceutical company, it does not currently distribute dividends. This security appeals to investors seeking exposure to early-stage drug development in rare disease treatment rather than current income.

VRDN performance versus SPY

Price and return data through 2026-10-16.

Total return is -99.1% over the past 12.3 years, 478.2 points behind SPY at 379.1%. Over the past year its total return — price change plus distributions reinvested — is -17.3%. Its deepest 1-year drawdown was 60.6%.

VRDN key facts

Asset type

Stock

Asset class

Equity

Inception date

06/18/2014

Distribution frequency

None

Last close

$19.03 (as of 2026-10-16)

Market cap

$2,155,951,879

Average volume

2457260.0

Payment date

11/13/2020

Beta

1.104

Payout ratio

0.0%

Forward P/E

1.0072

EPS

$-3.39

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

VRDN risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 60.6%.

Who may consider VRDN — and who may not

It is a weaker fit for investors who need monthly cash flow (VRDN does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on VRDN

• All tickers starting with V

Tagged: Healthcare.

Frequently asked questions